Abstract
Incidence and Outcomes of Drug Induced Liver Injury from Anti-Koch Treatment from January 2020 to July 2024
Jonathan L. De Luna, MD; Michael Angelo V. Chu, MD; Lovell B. Gatchalian, MD; Sarah D. Preza-Carmony, MD; Marilyn C. Talingdan-Te, MD; Felix L. Domingo, MD
East Avenue Medical Center
Significance: This study aims to determine the prevalence of drug induced liver injury in anti-tuberculosis treatment among patients treated at a tertiary hospital and identify treatment response based on the liver biochemical test.
Methodology: This is a single-center, retrospective cohort study which included 44 Filipino patients admitted and treated with Anti-Koch Treatment. Descriptive statistics was used to summarize the demographic, biochemical, and clinical characteristics. One-way ANOVA and Kruskal Wallis test was used to analyze significant differences in the measurement of the patient’s biochemical test.
Results: The incidence of drug induced liver injury from treatment of Anti-Koch treatment was documented to be 4.5% in the span of 5 years. There is a slight predominance of male and with hypertension as the more prevalent comorbidity in the study population. Treatment with Glycyrrhizic Acid + Glycine + L-Cysteine Hydrochloride in a statistically significant reduction in bilirubin(p-value 0.02) compared to other treatments and showed a trend to improving AST/ALT, however changes were not statistically significant. Mortalities among patients consisted predominantly due tmico acute respiratory failure as complication of community or hospital acquired pneumonia, there were no documented mortality due to DILI.
Conclusion: Drug induced liver injury from anti-koch treatment is a well-documented adverse event. The liver enzymes showed decline through withholding of offending drug and prescribing hepatoprotectant. These findings provide valuable insights into the epidemiology and outcomes of DILI, emphasizing the need for enhanced preventive strategies and management particularly in patients with significant comorbidities and those at risk of severe respiratory complications
Important Dates to Remember
| JRRE Activities 2023-2024 |
Proposed Dates |
|---|---|
| Resumption of face-to-face Evidence-Based Medicine Workshop Venue to be announced once finalized. |
July 21, 2023 (Friday), 1-5pm |
| Monthly Critical Appraisal of Topics Conferences to be gaciliated by Research Coordinators per Institution | Monthly Critical Appraisal of Topics Conferences per Institution |
| CAT Plenary/Liver Con Dates: September 23, 2023 December 16, 2023 March 2024 (During the JAC) Resumption of face-to-face Quarterly Critical Appraisal of Topics facilitated by the JRRE |
2 Clinical scenarios and articles are to be sent to institutions each on August 2023, November 2023, and February 2024; |
| Hybrid Research Workshop 4 week asynchronous via Moodle, followed by a 1 day on-site Onsite Workshop Research Protocol Presentation for Level I GI Fellows-In-Training - Research Protocol Presentation: August 12, 2023 - Research Forums of the Tripartite Societies |
Week 1: July 15-21, 2023 Week 2: July 22-28, 2023 Week 3: July 29-August 4, 2023 Week 4: August 5-11, 2023 |
| Research Manuscript Workshop for level II GI Fellows-In-Training | January 6, 2024 |